CHENGDU, China, March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals is invited to present at the 23rd ROTH Annual OC Growth Stock Conference from March 13 - 16, 2011 at the Ritz Carlton in Dana Point, California.
Dr. James Jiayuan Tong, Chief Financial Officer, Chief Business & Development Officer and Board Director of the Company will present at 8:30 am, March 16, at track 2 of the Conference.
An updated Company's presentation can be found on the Investors Relations of www.tianyinpharma.com
About TPITPI, headquartered at Chengdu, China, is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical medicine, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.
More information regarding the Company can be found at: http://www.tianyinpharma.com.
Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc.Web:
+86-28-8551-6696 (Chengdu, China)+86-134-3655-0011 (China)+1-949-350-6999 (U.S.)Address: 23rd Floor Unionsun Yangkuo PlazaNo 2 Block 3 South Renmin RoadChengdu, 610041China
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2010 PR Newswire.
All rights reserved